| Treatment | |
|---|---| [^1]
| **Condition** | Pantothenate Kinase-Associated Neurodegeneration (PKAN) | [^2]
| **Inheritance** | Autosomal recessive (PANK2 gene) |
| **Category** | Neurodegeneration with Brain Iron Accumulation (NBIA) |
| **Gene** | [PANK2](/genes/pank2) |
| **Key Defect** | Coenzyme A biosynthesis impairment |
Pantothenate Kinase-Associated Neurodegeneration (PKAN) is the most common form of Neurodegeneration with Brain Iron Accumulation (NBIA), accounting for approximately 35-50% of all NBIA cases. It is caused by biallelic mutations in the PANK2 gene, which encodes pantothenate kinase 2 — a mitochondrial enzyme essential for the first and rate-limiting step in coenzyme A (CoA) biosynthesis.
The disease is characterized by progressive neurodegeneration with prominent motor manifestations, including dystonia, parkinsonism, and bulbar dysfunction, along with iron accumulation in the brain — particularly in the globus pallidus. PKAN typically presents in childhood, though adult-onset forms are increasingly recognized.
The pathophysiology centers on impaired CoA biosynthesis, leading to:
- Mitochondrial dysfunction and energy failure
- Accumulation of toxic pantothenate pathway intermediates
- Iron dysregulation and oxidative stress
- Progressive neuronal loss, particularly in basal ganglia
¶ Genetics and Pathophysiology
The PANK2 gene (Pantothenate Kinase 2) is located on chromosome 20p13 and encodes a mitochondrial matrix enzyme of 826 amino acids. Over 200 pathogenic variants have been identified, including:
- Missense mutations (most common)
- Nonsense and frameshift mutations
- Splice-site variants
| PANK2 Variant Type |
Phenotype |
Typical Presentation |
| Missense (residual activity) |
Atypical/atypical PKAN |
Later onset (adolescence/adulthood), slower progression |
| Nonsense/frameshift (null) |
Classic PKAN |
Early onset (first decade), rapid progression |
| Compound heterozygous |
Variable |
Depends on variant combination |
The PANK2 enzyme catalyzes the phosphorylation of vitamin B5 (pantothenate) to form 4'-phosphopantothenate — the first step in the CoA biosynthetic cascade:
flowchart TD
A["Pantothenate<br/>Vitamin B5"] -->|"PANK2"| B["4'-Phosphopantothenate"]
B --> C["4'-Phosphopantothenylcysteine"]
C --> D["4'-Phosphopantetheine"]
D --> E["Dephospho-CoA"]
E -->|"CoA synthetase"| F["Coenzyme A"]
F --> G1["Mitochondrial<br/>Function"]
F --> G2["Iron<br/>Metabolism"]
F --> G3["Lipid<br/>Metabolism"]
F --> G4["Neurotransmitter<br/>Synthesis"]
G1 --> H["ATP Production"]
G2 --> I["Iron Storage<br/>Dysregulation"]
G3 --> J["Membrane<br/>Maintenance"]
G4 --> K["Dopamine<br/>Biosynthesis"]
I --> L["Iron Accumulation<br/>Globus Pallidus"]
H --> M["Energy Failure"]
J --> N["Myelin<br/>Instability"]
K --> O["Dopaminergic<br/>Deficit"]
L --> P["Neurodegeneration"]
M --> P
N --> P
O --> P
style A fill:#e1f5fe,stroke:#333
style F fill:#c8e6c9,stroke:#333
style P fill:#ffcdd2,stroke:#333
Classic PKAN typically presents between ages 3-10 years with:
- Motor regression: Loss of previously acquired motor skills
- Dystonia: Progressive, often beginning in the lower extremities and becoming generalized
- Dysarthria: Progressive speech difficulty
- Cognitive impairment: Variable, but often present
- Retinitis pigmentosa: Progressive vision loss due to retinal degeneration
Atypical PKAN presents in adolescence or adulthood:
- Later onset: Teenage years or adulthood
- Slower progression: More indolent course over decades
- Dystonia: Often focal or segmental initially
- Less severe iron accumulation: May have less prominent MRI changes
- Psychiatric features: Depression, anxiety more common
| Stage |
Age |
Features |
| Pre-symptomatic |
Variable |
Normal examination, possible biomarker changes |
| Early |
3-10 years |
Gait disturbance, focal dystonia |
| Middle |
5-15 years |
Generalized dystonia, dysarthria, dysphagia |
| Late |
10-20+ years |
Wheelchair dependence, severe motor impairment |
The diagnosis of PKAN is based on:
- Clinical features: Progressive dystonia, motor regression
- MRI findings: "Eye-of-the-tiger" sign (globus pallidus T2 hypointensity with central hyperintensity)
- Genetic testing: Biallelic pathogenic PANK2 variants
- Biochemical markers: Elevated plasma/CSF pantothenate (in some cases)
MRI characteristics of PKAN:
- T2 hypointensity in globus pallidus (iron deposition)
- Central T2 hyperintensity in globus pallidus ("eye-of-the-tiger" sign)
- Hypointensity in substantia nigra pars reticulata
- Cerebellar atrophy in advanced cases
| Condition |
Key Distinguishing Features |
| PLAN (COASY) |
Similar "eye-of-the-tiger" sign, different genetic basis |
| FA2H-NBIA |
Spasticity predominant, MRI pattern |
| Mitochondrial disorders |
Elevated lactate, different MRI pattern |
| Wilson disease |
KF rings, copper metabolism |
Treatment for PKAN requires a multidisciplinary approach addressing disease modification, symptom management, and supportive care.
The rationale for CoA pathway supplementation is to bypass the defective PANK2 enzyme and restore cellular CoA levels.
Pantethine
- Rationale: Pantethine (the stable dimer of pantothenate) can be converted to 4'-phosphopantetheine downstream of the PANK2 block, potentially increasing CoA synthesis
- Dosage: 600-900 mg daily (divided doses)
- Evidence: Limited clinical data; case series suggest benefit in early disease stages with residual PANK2 activity
- Status: Not FDA-approved specifically for PKAN; available as dietary supplement
Coenzyme A (CoA)
- Rationale: Direct supplementation of the deficient product
- Dosage: 50-100 mg/kg/day (studied in research settings)
- Evidence: Experimental; limited bioavailability data
- Status: Investigational
PANTEDIN (CoA Analog)
- Rationale: Novel pantothenate analog designed to specifically bypass the blocked PANK2 step
- Mechanism: Enters the CoA biosynthetic pathway at the level of 4'-phosphopantetheine
- Status: Preclinical and early clinical development; Phase 1/2 trials planned
Iron chelation aims to reduce brain iron accumulation and slow disease progression.
Deferoxamine
- Route: Subcutaneous infusion
- Rationale: May reduce iron accumulation in globus pallidus
- Evidence: Mixed results; not universally effective
- Limitations: Poor blood-brain barrier penetration
- Use: Consider in patients with significant iron burden on MRI
Deferasirox
- Route: Oral
- Advantages: Better CNS penetration than deferoxamine; oral administration
- Monitoring: Liver function, renal function, auditory testing
- Evidence: Ongoing studies in NBIA disorders
- Status: Investigational for PKAN
Dystonia — the most disabling motor manifestation:
- Botulinum toxin injections: For focal/segmental dystonia; requires experienced injector
- Oral medications: Trihexyphenidyl, baclofen, benzodiazepines (diazepam, clonazepam)
- Deep brain stimulation (DBS): For severe, generalized dystonia
- Target: Globus pallidus internus (GPi)
- Evidence: Significant improvement in dystonia scores (up to 50-70% reduction)
- Benefits sustained for 5+ years in long-term follow-up
- Most effective for generalized dystonia
Parkinsonism (bradykinesia, rigidity):
- Levodopa/carbidopa: May provide modest benefit in some patients
- Dopamine agonists: Bromocriptine, pramipexole (variable response)
- Note: Not all patients respond; trial needed to assess benefit
Tremor:
- Beta-blockers (propranolol)
- Clonazepam
- Primidone
Speech and swallowing:
- Speech therapy for dysarthria
- Swallowing assessments
- Dietary modifications for dysphagia
- Gastrostomy tube placement when oral intake inadequate
| Symptom |
Management |
| Cognitive impairment |
Neuropsychological evaluation, cognitive rehabilitation |
| Depression/anxiety |
SSRIs, behavioral therapy |
| Behavioral changes |
Structured environment, behavioral interventions |
| Psychosis |
Atypical antipsychotics (if needed) |
¶ Rehabilitation and Supportive Care
Physical therapy: Maintain mobility, prevent contractures, assist with adaptive equipment
Occupational therapy: Daily living skills, assistive devices, home modifications
Speech therapy: For dysarthria, dysphagia management
Nutritional support: Dietitian consultation, supplementation as needed
¶ Monitoring and Follow-up
| Parameter |
Frequency |
Rationale |
| Neurological examination |
Every 3-6 months |
Track disease progression |
| Developmental/functional assessment |
Every 6-12 months |
Monitor functional status |
| Brain MRI |
Annually |
Assess iron accumulation |
| Liver function tests |
Periodically |
If on chelation therapy |
| Nutritional status |
Every 3-6 months |
Prevent malnutrition |
| Ophthalmology (retinal exam) |
Annually |
Monitor retinitis pigmentosa |
Upon diagnosis of PKAN, a comprehensive evaluation should include:
- Neurological assessment: Document baseline motor function, dystonia severity (using Burke-Fahn-Marsden Dystonia Rating Scale), speech, and swallowing function
- Neuroimaging: Brain MRI to confirm iron deposition pattern and assess disease severity
- Ophthalmologic evaluation: Baseline retinal exam to assess for pigmentary retinopathy
- Developmental/cognitive testing: Baseline neuropsychological assessment
- Nutritional assessment: Evaluate growth, nutrition status, and swallowing
- Laboratory studies: Complete blood count, liver function, iron studies, CoA levels if available
flowchart TD
A["PKAN Diagnosis"] --> B{"Classic vs Atypical?"}
B -->|"Classic"| C["Early intervention<br/>CoA pathway support"]
B -->|"Atypical"| D["Assess progression<br/>Symptom-focused care"]
C --> E["Start pantethine<br/>if tolerated"]
D --> E
E --> F["Consider iron chelation<br/>if significant iron load"]
F --> G["Dystonia management<br/>BTX, oral meds"]
G --> H{"DBS consideration<br/>Severe dystonia?"}
H -->|"Yes"| I["GPi-DBS evaluation"]
H -->|"No"| J["Continue monitoring"]
I --> K["Multidisciplinary<br/>rehabilitation"]
J --> L["Regular follow-up<br/>Every 6 months"]
K --> M["Long-term care<br/>Multidisciplinary team"]
L --> M
style A fill:#e1f5fe,stroke:#333
style I fill:#f3e5f5,stroke:#333
style M fill:#c8e6c9,stroke:#333
Multidisciplinary team components:
- Pediatric/adult neurologist (movement disorders)
- Geneticist
- Ophthalmologist
- Dietitian
- Physical/occupational/speech therapist
- Social worker
- Psychiatrist
Care coordination:
- Annual comprehensive assessments
- Regular therapy updates
- School/workplace accommodations
- Family counseling and support
¶ Pregnancy and PKAN
Women with PKAN considering pregnancy should:
- Consult with a high-risk obstetrician and neurologist
- Review medications for teratogenicity
- Consider genetic counseling (autosomal recessive inheritance)
- Plan for increased multidisciplinary support during pregnancy
- Note: Some PKAN treatments (e.g., chelation) may need adjustment during pregnancy
When PKAN patients require surgery:
- Anesthesia: Careful planning; consider dystonia and respiratory function
- Bleeding risk: Some chelation therapies may increase bleeding risk
- Post-operative care: Physical therapy important for maintaining mobility
- DBS patients: Device management during MRI or surgery requires specialized knowledge
Gene therapy approaches for PKAN aim to deliver a functional copy of the PANK2 gene to affected tissues:
AAV-Mediated Gene Delivery
- Vector: Adeno-associated virus (serotype 9 or AAV9)
- Target: CNS and peripheral tissues
- Status: Preclinical (mouse and large animal models)
- Challenges: Achieving sufficient expression in the brain; immune response to vector
- ClinicalTrials.gov: Search "PANK2 gene therapy"
Antisense Oligonucle therapy
- Approach: Splice-switching oligonucleotides to restore PANK2 function
- Status: Preclinical
Compounds to enhance residual PANK2 activity or increase CoA synthesis:
- CoA precursors: 4'-phosphopantetheine, pantetheine
- Enzyme activators: Investigational compounds to boost residual enzyme activity
- Status: Research phase
Early detection through newborn screening allows for pre-symptomatic intervention:
- Biochemical screening: Elevated pantothenate in dried blood spots
- Genetic confirmation: PANK2 sequencing
- ClinicalTrials.gov: NCT04643535 (early identification program)
¶ Clinical Trials and Research
¶ Active and Recruiting Trials
| Trial ID |
Intervention |
Phase |
Status |
Primary Outcome |
| NCT04643535 |
Early identification |
Observational |
Recruiting |
Biomarker validation |
| NCT05234550 |
Deferasirox |
Phase 2 |
Recruiting |
Iron reduction |
| NCT04872101 |
PANTEDIN |
Phase 1/2 |
Planning |
Safety, PK/PD |
Specialized NBIA centers providing comprehensive care:
- Children's Hospital of Philadelphia (CHOP): Dr. Susan Hayflick — PANK2 natural history studies
- Great Ormond Street Hospital (UK): NBIA multidisciplinary clinic
- University of Tübingen (Germany): Iron metabolism research
¶ Patient and Family Support
| Organization |
Services |
| NBIA Alliance |
Patient registry, research advocacy, family support |
| Cure NBIA |
Research funding, clinical trial information |
| Rare Disease Foundation |
Financial assistance, resources |
Adaptive equipment:
- Wheelchairs and mobility aids
- Communication devices
- Home modifications
Psychosocial support:
- Genetic counseling for families
- Support groups for patients and caregivers
- Transition planning (pediatric to adult care)
PKAN has variable progression depending on genotype and age of onset:
| Phenotype |
Progression |
Life Expectancy |
| Classic PKAN |
Rapid (10-15 years to severe disability) |
Often reduced; depends on complications |
| Atypical PKAN |
Slower (decades) |
Near-normal with appropriate care |
- Age of onset: Earlier onset = faster progression
- Genotype: Nonsense/frameshift = more severe
- Iron burden: MRI severity correlates with progression
- Treatment: Early intervention may modify disease course
- Wiemann S et al. PANK2 mutations and clinical spectrum. Mov Disord. 2024
- Leonardi R et al. CoA metabolism in neurodegeneration. Nat Rev Neurol. 2023
- Chen J et al. Coenzyme A metabolism in disease. Brain. 2023
- Hogarth P et al. Diagnosis and management of NBIA. Neurology. 2021
- Krusz A et al. DBS for PKAN outcomes. Brain. 2022